28 results on '"Sackmann, F."'
Search Results
2. PB1425 High Cell-free (cf)DNA in Patients with Myelofibrosis (MF) is Associated with Adverse Clinical Outcomes, Activation of the AIM2 Inflammasome and Elevated Levels of Inflammasome-Related Cytokine IL-18
3. P1082: SAFETY AND EFFICACY ANALYSIS IN OLDER PATIENTS TREATED WITHIN THE GATLA LH-05 PROTOCOL: PET-ADAPTED THERAPY AFTER 3 CYCLES OF ABVD FOR ALL STAGES OF HODGKIN LYMPHOMA
4. P1081: PET-ADAPTED THERAPY AFTER THREE CYCLES OF ABVD FOR ALL STAGES OF HODGKIN LYMPHOMA: LONG TERM FOLLOW UP OF THE GATLA LH-05 TRIAL
5. RESULTS OF MUTATIONAL STATUS OF IMMUNOGLOBULIN HEAVY-CHAIN VARIABLE GENES ANALYSIS IN A COHORT OF PATIENTS WITH B-CLL. A SINGLE CENTRE EXPERIENCE
6. P120 Decitabine in myelodysplastic syndromes, 18 months of follow up: Argentine initial multi-institutional clinical experience
7. P010 Myelodysplastic syndromes, pilot register, first results. Grupo de Estudio de Sindromes Mielodisplasicos. Sociedad Argentina de Hematologia
8. SAFETY AND EFFICACY ANALYSIS OF ELDERLY PATIENTS TREATED WITHIN THE GATLA HL-05 CLINICAL TRIAL: PET ADAPTED THERAPY AFTER 3 CYCLES OF ABVD FOR ALL STAGES OF HODGKIN LYMPHOMA
9. SYMPTOMS, RISK CLASSIFICATION, AND SPLEEN SIZE IN JAK2 INHIBITOR-NAIVE MYELOFIBROSIS : IMPLICATIONS FOR JAK2 INHIBITOR TREATMENT
10. Development Of An Mf Patient Reported Outcome (Pro) Tool For Fda Qualification : Comprehensive Literature Search And Physician Cognitive Debriefing Results
11. Impact Of Splenomegaly On Mpn Symptoms And Association With Clinical Features : An Analysis By The Mpn Quality Of Life International Study Group
12. Symptomatic burden in myelofibrosis (MF): Prospective international assessment in 128 MF patients.
13. Prognostic factors in monoclonal gammopathy of undetermined significance
14. Untersuchungen zum Mindestversuchsaufwand bei Lebensdaueruntersuchungen an einem Wälzgetriebe.
15. 45 TESTICULAR FUNCTION IN LEUKEMIC PATIENTS AFTER CHRONIC TREATMENT WITH CYTOSTATIC DRUGS
16. High cell-free DNA is associated with disease progression, inflammasome activation and elevated levels of inflammasome-related cytokine IL-18 in patients with myelofibrosis.
17. Gastric Lanthanosis-A Rare Place to Find a Rare-Earth Element.
18. PET-adapted therapy after three cycles of ABVD for all stages of Hodgkin lymphoma: results of the GATLA LH-05 trial.
19. Symptom burden profile in myelofibrosis patients with thrombocytopenia: Lessons and unmet needs.
20. Associations between gender, disease features and symptom burden in patients with myeloproliferative neoplasms: an analysis by the MPN QOL International Working Group.
21. Symptomatic Profiles of Patients With Polycythemia Vera: Implications of Inadequately Controlled Disease.
22. Distinct clustering of symptomatic burden among myeloproliferative neoplasm patients: retrospective assessment in 1470 patients.
23. Myeloproliferative neoplasm (MPN) symptom assessment form total symptom score: prospective international assessment of an abbreviated symptom burden scoring system among patients with MPNs.
24. Decitabine in myelodysplastic syndromes and chronic myelomonocytic leukemia: Argentinian/South Korean multi-institutional clinical experience.
25. Clinical significance of V617F mutation of the JAK2 gene in patients with chronic myeloproliferative disorders.
26. [Treatment of primary sclerosing cholangitis: drug, endoscopic, combined or no treatment at all?].
27. [Bleeding after endoscopic biopsy and polypectomy--do nonsteroidal anti-rheumatic drugs increase the risk?].
28. [Clinical evaluation of daunomycin combined with vincristine and prednisone in the treatment of acute leukemias].
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.